By Stanford Medicine – ScienceDaiiy –
A Stanford-led team has replaced toxic pre-transplant chemotherapy with a targeted antibody, allowing children with Fanconi anemia to receive stem cell transplants safely. The antibody, briquilimab, removes diseased stem cells without radiation, enabling nearly complete donor cell replacement. The approach also widens donor eligibility and could soon be applied to other bone marrow failure diseases.
A new antibody therapy developed at Stanford Medicine has shown that it can prepare patients for stem cell transplants without the need for toxic chemotherapy or radiation, according to results from a phase 1 clinical trial.
